Pharma BD Deal Intelligence
An $8.5B oncology alliance that made Lynparza the dominant PARP inhibitor across ovarian, breast, prostate, and pancreatic cancers. Merck paid $1.6B upfront, betting that combining PARP inhibition with Keytruda's PD-1 blockade would create the next standard of care.
AstraZeneca taps Merck in $8.5B cancer deal to co-develop and co-commercialize Lynparza both as monotherapy and in combination with their respective PD-L1 and…
AstraZeneca and Merck enter an $8.5 billion oncology collaboration combining Lynparza with each company's immuno-oncology assets, reflecting the growing…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Merck and AstraZeneca formed a global strategic oncology collaboration to co-develop and co-commercialize Lynparza (olaparib) and selumetinib. Merck paid $1.6B upfront plus $750M for license options, with up to $6.15B in regulatory and sales milestones. The companies share development costs and profits for both solo and combination therapies with their respective PD-1/PD-L1 agents.
310K US cases/yr · $35.0B Global breast cancer therapeutics
Breast cancer is the most common cancer in women worldwide. Treatment is guided by molecular subtype: HR+/HER2-, HER2+, and triple-negative. CDK4/6 inhibitors have transformed HR+ metastatic disease, and ADCs are reshaping later-line treatment.
HR+/HER2-: CDK4/6 inhibitor + endocrine therapy. HER2+: trastuzumab + pertuzumab + chemo, T-DXd in 2L+. TNBC: pembrolizumab + chemo. Key players: Pfizer (Ibrance), Lilly (Verzenio), Novartis (Kisqali), Daiichi Sankyo/AZ (Enhertu), Gilead (Trodelvy).
300K US cases/yr · $18.0B Global prostate cancer therapeutics
5-year relative survival ~97.9% overall; ~37.9% for distant (metastatic) disease per SEER 2015-2021.
Localized: surgery, radiation, active surveillance. mHSPC: ADT + abiraterone or enzalutamide. mCRPC: abiraterone, enzalutamide, PARP inhibitors, Lu-177 PSMA. Key players: J&J (Erleada, Zytiga), Pfizer (Xtandi), AZ (Lynparza), Novartis (Pluvicto), Bayer (Nubeqa).
200K US cases/yr · $30.0B Global NSCLC therapeutics
Non-small cell lung cancer (NSCLC) is a type of cancer that forms in the tissues of the lung and is the most common form of lung cancer, more prevalent than small cell lung cancer. Its three major histologic subtypes are adenocarcinoma, squamous cell carcinoma (also called epidermoid carcinoma), and large cell carcinoma; less common variants include adenosquamous carcinoma, sarcomatoid carcinoma, salivary gland carcinoma, and carcinoid tumors. NSCLC typically presents with persistent cough, breathing difficulties, chest discomfort, wheezing, blood in sputum, hoarseness, loss of appetite, unexplained weight loss, fatigue, trouble swallowing, or facial swelling, although early-stage disease often causes no signs or symptoms. Smoking is the major risk factor, with additional contributions from secondhand smoke, occupational exposures, radiation, and family history. Because symptoms are frequently absent until the disease is locally advanced or metastatic, many patients are diagnosed at stages at which cure is unlikely, and current treatments do not provide cure for most patients. Management depends on stage and molecular profile and can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with clinical trials offering additional investigational options for patients with non-small cell lung cancer.
No driver mutation: pembrolizumab +/- chemo. EGFR+: osimertinib. ALK+: alectinib, lorlatinib. KRAS G12C: sotorasib. Key players: Merck (Keytruda $25B+), Roche (Tecentriq), AZ (Tagrisso $5B+, Imfinzi), Pfizer (Lorbrena), Amgen (Lumakras).
20K US cases/yr · $5.0B Global ovarian cancer therapeutics
Ovarian cancer is the deadliest gynecologic malignancy. PARP inhibitors have transformed maintenance therapy for BRCA-mutated and HRD-positive disease. Most patients present at advanced stages.
Surgery + platinum-based chemo. Maintenance: PARP inhibitors (olaparib, niraparib) for HRD+. Bevacizumab in combination. Key players: AZ/Merck (Lynparza), GSK (Zejula), Clovis (Rubraca), Roche (Avastin).
Merck paid $1.6B upfront plus up to $6.9B in milestones to co-develop and co-commercialize Lynparza across multiple cancers.
Lynparza gained approvals in ovarian, breast, prostate, and pancreatic cancers, becoming dominant PARP inhibitor.
Global sales hit $3.67B with profits shared equally between Merck and AstraZeneca.
Key US patents expire 2027-2031; EU SPC runs to 2029. Revenue decline of 8-15% expected post-cliff.
Highly Successful Partnership. Assessment of Merck & Co. Inc.'s $8.5B acquisition of AstraZeneca PLC and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / AstraZeneca PLC (this deal) | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2017 deals · Merck & Co. Inc. deals · Oncology deals